Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus

doi:10.3748/wjg.v24.i13.1478

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 24, Issue 13

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6735)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-5) series, Tables (1-3) series.

Item

Count

PDF

339

WORD

181

HTML

3427

Figures (1-5)

159

Tables (1-3)

145

Sum=4251

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1055

Download

1429

Sum=2484

Apr 7, 2018 (publication date) through Apr 15, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Apr 7, 2018; 24(13): 1478-1485
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1478

Table 3 Assessment of patients with history of hepatitis C virus

	SVR (n = 23)	Non SVR (n = 6)	P value
Alpha fetoprotein	9.6 (1.7-348.9)	5.3 (2.6-65.7)	0.2815
Latest treatment for HCC			0.2558
Surgical resection or Radiofrequency ablation	73.9% (17)	66.6% (6)
Transcatheter arterial chemoembolization	26.1% (6)	16.7% (1)
Radiation for bone metastasis	0% (0)	16.7% (1)
Recurrent HCC within 1 yr from the end of SOF/RBV	65. 2% (15)	83.3% (5)	0.6328

SVR: Sustained virological response; HCC: Hepatocellular carcinoma; SOF/RBV: Sofosbuvir/ribavirin.

Citation: Yada M, Miyazaki M, Tanaka K, Masumoto A, Motomura K. Hepatocellular carcinoma or interferon-based therapy history attenuates sofosbuvir/ribavirin for Japanese genotype 2 hepatitis C virus. World J Gastroenterol 2018; 24(13): 1478-1485
URL: https://www.wjgnet.com/1007-9327/full/v24/i13/1478.htm
DOI: https://dx.doi.org/10.3748/wjg.v24.i13.1478